Derm-Biome-Pharmaceuticals.png
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
12 oct. 2022 10h00 HE | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
TIP_link_300x300.jpg
$11+ Billion Dermatology Devices Market Size to Grow at 11.2% CAGR, Globally, by 2028 - Growing Prevalence of Skin Cancers and Skin Disorders
30 sept. 2022 08h00 HE | The Insight Partners
New York, Sept. 30, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology Devices Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast...
logo 600X600.png
Global Immune Checkpoint Inhibitors Market to Surpass US$ 3,902.9 Million by 2030, Says Coherent Market Insights (CMI)
29 août 2022 08h40 HE | CMI
Seattle, Aug. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market is estimated to be valued at US$ 1,444.7 million in 2022 and is...
immunocore-logo-2018
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
10 août 2022 07h00 HE | Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
immunocore-logo-2018
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
01 août 2022 07h00 HE | Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
TIP_link_300x300.jpg
Prostate Cancer Nuclear Medicine Diagnostics Market to Hit $1,315.66 million by 2028 at 10.6% CAGR - Says, The Insight Partners
25 juil. 2022 10h30 HE | The Insight Partners
New York, July 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global...
immunocore-logo-2018
Immunocore Announces $140 Million Private Placement Financing
18 juil. 2022 07h00 HE | Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...
Global Monoclonal Antibodies for Oncology Market
Monoclonal Antibodies for Oncology Global Market Report 2022
08 juil. 2022 05h43 HE | Research and Markets
Dublin, July 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed...
immunocore-logo-2018
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
03 juin 2022 07h00 HE | Immunocore Holdings Limited
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous...
Vantage Market Research.png
Dermatology Devices Market to Hit USD 23.43 Billion By 2028; Dermatology Devices Industry CAGR of 11.5% Between 2022-2028; Exclusive Insight Report by Vantage Market Research
05 mai 2022 08h03 HE | Vantage Market Research
WASHINGTON, May 05, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Dermatology Devices Market finds that Rising incidence of skin disorders, increasing awareness on...